Sensitivity improvement of the LC–MS/MS quantification of carbidopa in human plasma and urine by derivatization with 2,4-pentanedione

The reliable quantification of carbidopa in biological samples at low concentrations is challenging because of the polar and highly unstable nature of the compound. In this paper, LC–MS/MS methods are described for the
determination of carbidopa in 50 μL of human plasma and 25 μL of human urine in the concentration ranges 1–1,000 ng/mL and 100–50,000 ng/mL, respectively. After a simple protein precipitation (plasma) or dilution
(urine) step, carbidopa is derivatized at its hydrazine moiety by reaction for one hour with 2,4-pentanedione under acidic conditions and at 40 °C. The product is a relatively non-polar molecule that is suitable for reversedphase
liquid chromatography (3.5 min run time) with detection by tandem mass spectrometry with electrospray ionization. A stable-isotope labeled internal standard is used for response normalization. Precision, accuracy and
selectivity of the methods meet the criteria of international guidelines for bioanalytical method validation. Acidification of urine to pH 1.5 and the addition of two anti-oxidants (5 mg/mL sodium metabisulfite and 1 mg/
mL butylated hydroxytoluene) to plasma, in combination with sampling and analysis on ice and under yellow light, ensure sufficient stability of carbidopa. The methods were successfully used to determine plasma pharmacokinetics
and urinary excretion of carbidopa in healthy volunteers after a single 37.5 mg oral dose.